Abstract
Chemotherapy induces inevitable adverse effects, while complementary and alternative medicine employs many chemical substances. Herb pairs normally contain two herbal medicines, and they have satisfactory effects on cancer therapy. Zuojinwan, a well-known herb pair, is composed of Coptidis Rhizoma and Euodiae Fructus. Berberine and evodiamine are considered the most important compounds in the Zuojinwan herb pair. Previous reports have shown that combined use of evodiamine and berberine displays synergistic anticancer activities in various types of cancers, but this combination has not been tested in colorectal cancer. Hence, this study aimed to explore the combined effects of evodiamine and berberine on colorectal cancer cell lines and cardiomyocytes. We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis. However, berberine did not increase the cytotoxicity of evodiamine in normal human colon mucosal epithelial cells. Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways. Therefore, we suggest that the combination of berberine and evodiamine displays high anticancer activity while reducing the side effects in specific cell lines.
PMID: 32109457 [PubMed - as supplied by publisher]
➖ Sent by @TheFeedReaderBot ➖
14:15
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:15
In reply to this message
pubmed: tutte cardiotoxicity...
Montelukast ameliorates doxorubicin-induced cardiotoxicity via modulation of p-glycoprotein and inhibition of ROS-mediated TNF-α/NF-κB pathways.
Related Articles
Montelukast ameliorates doxorubicin-induced cardiotoxicity via modulation of p-glycoprotein and inhibition of ROS-mediated TNF-α/NF-κB pathways.
Drug Chem Toxicol. 2020 Feb 27;:1-12
Authors: Hafez HM, Hassanein H
Abstract
Doxorubicin (DOX) cardiotoxicity remains an obstacle to clinical use. The current study examined the possible role of montelukast (ML), which is a cysteinyl leukotrienes receptor antagonist against DOX-induced cardiotoxicity. Male Wistar rats were divided into five groups. The control group, ML group, DOX-challenged group, and DOX/ML-treated groups received ML10 and 20 mg/kg/day for 14 days. Cardiac enzymes; lactate dehydrogenase (LDH); and creatine kinase MB (CK-MB) isoenzymes in serum were measured. Cardiac oxidative/antioxidative parameters were also measured. Cardiac samples were examined for histological images and immunohistochemical expression of tumor necrosis factor alpha (TNF-α)/survivin. Quantitative real-time-polymerase chain reaction was used to detect levels of interleukin (IL)-1β/caspase-3 mRNA. The levels of P-glycoprotein (P-gp), nuclear factor-kappa B , and reactive oxygen species were estimated by enzyme-linked immunosorbent assay. DOX increased serum cardiac enzymes along with oxidative, inflammatory, and apoptotic markers. Both doses of ML significantly ameliorated cardiac enzymes and attenuated all oxidative stress parameters with the enhancement of P-gp activity. It was concluded that ML may be a valuable cardioprotective adjuvant during DOX use.
PMID: 32106718 [PubMed - as supplied by publisher]
➖ Sent by @TheFeedReaderBot ➖
1 March 2020
14:43
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:43
In reply to this message
pubmed: tutte cardiotoxicity...
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
Related Articles
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
Eur Heart J. 2020 Feb 29;:
Authors: Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG
Abstract
AIMS: Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are presented.
METHODS AND RESULTS: From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF ≥50%. Late gadolinium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort. Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26% of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology. Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of 5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.
CONCLUSION: These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-associated myocarditis.
PMID: 32112560 [PubMed - as supplied by publisher]
14:43
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:43
In reply to this message
pubmed: tutte cardiotoxicity...
Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with (R)-CHOP regimen.
Related Articles
Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with (R)-CHOP regimen.
Echocardiography. 2020 Feb 28;:
Authors: Wang B, Yu Y, Zhang Y, Hao X, Zhao H, Yang S, Sun Q, Wang Y
Abstract
BACKGROUND: Despite speckle tracking echocardiography (STE) has emerged as a sensitive technique for identifying myocardial dysfunction, there are little data available on the appropriate timing to perform STE in the serial assessment after anthracycline administration. Moreover, further uncertainty is increased in the context of STE application in diffuse large B-cell lymphoma (DLBCL) research, as most recommendations are inferred by studies conducted primarily in breast cancer.
OBJECTIVE: This study aimed to determine whether early measurement of strain parameters derived by STE could predict the development of cardiotoxicity.
METHODS: Sixty-five patients were included in the final analysis. The patients were evaluated at baseline, after the third cycle and sixth-eighth cycle, and during follow-up. Global longitudinal strain (GLS) was analyzed using STE, and left ventricular ejection fraction (LVEF) was calculated by real time 3D echocardiography (RT3DE).
RESULTS: There was a significant decrease in GLS after the third cycle of chemotherapy and remained decreased during subsequent follow-up, whereas LVEF decreased only at follow-up. A percentage reduction in GLS of 13.8% between baseline and the third cycle of chemotherapy was the best predictor of further LVEF reduction.
CONCLUSION: Earlier monitoring timing and more accurate assessment methods might be helpful in the prevention of irreversible heart failure.
PMID: 32112477 [PubMed - as supplied by publisher]
3 March 2020
13:04
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:04
In reply to this message
pubmed: tutte cardiotoxicity...
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.
Related Articles
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.
Circulation. 2019 05 21;139(21):e997-e1012
Authors: Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, La Gerche A, Ligibel JA, Lopez G, Madan K, Oeffinger KC, Salamone J, Scott JM, Squires RW, Thomas RJ, Treat-Jacobson DJ, Wright JS, American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease
Abstract
Cardiovascular disease is a competing cause of death in patients with cancer with early-stage disease. This elevated cardiovascular disease risk is thought to derive from both the direct effects of cancer therapies and the accumulation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespiratory fitness. Effective and viable strategies are needed to mitigate cardiovascular disease risk in this population; a multimodal model such as cardiac rehabilitation may be a potential solution. This statement from the American Heart Association provides an overview of the existing knowledge and rationale for the use of cardiac rehabilitation to provide structured exercise and ancillary services to cancer patients and survivors. This document introduces the concept of cardio-oncology rehabilitation, which includes identification of patients with cancer at high risk for cardiac dysfunction and a description of the cardiac rehabilitation infrastructure needed to address the unique exposures and complications related to cancer care. In this statement, we also discuss the need for future research to fully implement a multimodal model of cardiac rehabilitation for patients with cancer and to determine whether reimbursement of these services is clinically warranted.
PMID: 30955352 [PubMed - indexed for MEDLINE]
13:04
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
13:04
In reply to this message
pubmed: tutte cardiotoxicity...
Cardiac Magnetic Resonance T1 Mapping in Adolescent and Young Adult Survivors of Childhood Cancers.
Related Articles
Cardiac Magnetic Resonance T1 Mapping in Adolescent and Young Adult Survivors of Childhood Cancers.
Circ Cardiovasc Imaging. 2019 04;12(4):e008453
Authors: Tong X, Li VW, Liu AP, So EK, Chan Q, Ho KK, Yau JP, Cheuk DK, Cheung YF, Ng MY
PMID: 30929466 [PubMed - indexed for MEDLINE]
4 March 2020
14:31
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:31
In reply to this message
pubmed: tutte cardiotoxicity...
Personalized Approach to Cancer Treatment-Related Cardiomyopathy.
Related Articles
Personalized Approach to Cancer Treatment-Related Cardiomyopathy.
Curr Heart Fail Rep. 2020 Mar 03;:
Authors: Slivnick J, Vallakati A, Addison D, Wallner A, Tong MS
Abstract
PURPOSE OF REVIEW: Cancer treatment-related cardiotoxicity (CTRC) represents a significant cause of morbidity and mortality worldwide. The purpose of our review is to summarize the epidemiology, natural history, and pathophysiology of cardiotoxicity-related to cancer treatment. We also summarize appropriate screening, surveillance, and management of CTRC. While cardiotoxicity is characteristically associated with anthracyclines, HER2-B antagonists, and radiation therapy (XRT), there is growing recognition of toxicity with immune checkpoint inhibitors (ICI), tyrosine kinase inhibitors, and proteasome inhibitors.
RECENT FINDINGS: Patients at risk for cardiotoxicity should be screened based on available guidelines, generally with serial echocardiograms. The role of medical heart failure (HF) therapies is controversial in patients with asymptomatic left ventricular dysfunction but may be considered in some instances. Once symptomatic HF has developed, treatment should be in accordance with ACC/AHA guidelines. The goal in caring for patients receiving cancer treatment is to optimize cardiac function and prevent interruptions in potentially lifesaving cancer treatment.
PMID: 32125627 [PubMed - as supplied by publisher]
14:31
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:31
In reply to this message
pubmed: tutte cardiotoxicity...
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.
Related Articles
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.
Mol Ther Oncolytics. 2020 Mar 27;16:207-218
Authors: Liu H, Xue YC, Deng H, Mohamud Y, Ng CS, Chu A, Lim CJ, Lockwood WW, Jia WWG, Luo H
Abstract
We recently discovered that coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS mutant lung adenocarcinoma. Nevertheless, the evident toxicity restricts the use of wild-type (WT)-CVB3 for cancer therapy. The current study aims to engineer the CVB3 to decrease its toxicity and to extend our previous research to determine its safety and efficacy in treating TP53/RB1 mutant small-cell lung cancer (SCLC). A microRNA-modified CVB3 (miR-CVB3) was generated via inserting multiple copies of tumor-suppressive miR-145/miR-143 target sequences into the viral genome. In vitro experiments revealed that miR-CVB3 retained the ability to infect and lyse KRAS mutant lung adenocarcinoma and TP53/RB1-mutant SCLC cells, but with a markedly reduced cytotoxicity toward cardiomyocytes. In vivo study using a TP53/RB1-mutant SCLC xenograft model demonstrated that a single dose of miR-CVB3 via systemic administration resulted in a significant tumor regression. Most strikingly, mice treated with miR-CVB3 exhibited greatly attenuated cardiotoxicities and decreased viral titers compared to WT-CVB3-treated mice. Collectively, we generated a recombinant CVB3 that is powerful in destroying both KRAS mutant lung adenocarcinoma and TP53/RB1-mutant SCLC, with a negligible toxicity toward normal tissues. Future investigation is needed to address the issue of genome instability of miR-CVB3, which was observed in ~40% of mice after a prolonged treatment.
PMID: 32123721 [PubMed]
14:31
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:31
In reply to this message
pubmed: tutte cardiotoxicity...
[Immune checkpoint inhibitor-related cardiotoxicities].
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--medjournals.cn-CMAPH-Linkout-logo.png //www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--journal.yiigle.com-r-cms-jiansuo-CMAPH-Linkout-logo.png Related Articles
[Immune checkpoint inhibitor-related cardiotoxicities].
Zhonghua Nei Ke Za Zhi. 2020 01 01;59(1):75-77
Authors: Zhou L, Li HW, Chen H
PMID: 31887842 [PubMed - indexed for MEDLINE]
14:31
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:31
In reply to this message
pubmed: tutte cardiotoxicity...
Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--pubs.acs.org-images-pubmed-acspubs.jpg Related Articles
Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.
J Med Chem. 2019 03 28;62(6):3135-3146
Authors: Huang W, Hulverson MA, Choi R, Arnold SLM, Zhang Z, McCloskey MC, Whitman GR, Hackman RC, Rivas KL, Barrett LK, Ojo KK, Van Voorhis WC, Fan E
Abstract
Cryptosporidium is a leading cause of pediatric diarrhea worldwide. Currently, there is neither a vaccine nor a consistently effective drug available for this disease. Selective 5-aminopyrazole-4-carboxamide-based bumped-kinase inhibitors (BKIs) are effective in both in vitro and in vivo models of Cryptosporidium parvum. Potential cardiotoxicity in some BKIs led to the continued exploration of the 5-aminopyrazole-4-carboxamide scaffold to find safe and effective drug candidates for Cryptosporidium. A series of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (mouse infection model) assays and safety issues. Compound 6 (BKI 1708) was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of toxicity up to 200 mg/kg dosed QD for 7 days. Compound 15 (BKI 1770) was found to be efficacious at 30 mg/kg dosed twice daily (BID) for 5 days with no observable signs of toxicity up to 300 mg/kg dosed QD for 7 days. Compounds 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety parameters and efficacy in the mouse model of cryptosporidiosis.
PMID: 30830766 [PubMed - indexed for MEDLINE]
5 March 2020
12:02
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
12:02
In reply to this message
pubmed: tutte cardiotoxicity...
Right ventricular involvement in cancer therapy-related cardiotoxicity: the emerging role of strain echocardiography.
Related Articles
Right ventricular involvement in cancer therapy-related cardiotoxicity: the emerging role of strain echocardiography.
Heart Fail Rev. 2020 Mar 03;:
Comments
Post a Comment
اكتب تعليق حول الموضوع